Table 2.
Safety of three bowel cleansing regimens.
| Adverse event | PEG-bisacodyl group, N = 41 | PEG-ELS group, N = 43 | NaPico+MgCit group, N = 39 | All groups, N = 123 | p |
|---|---|---|---|---|---|
| Overall | 25 (61%) | 30 (69.8%) | 18 (46.2%) | 73 (59.3%) | ∗ |
| Abdominal pain | 13 (31.7%) | 16 (37.2%) | 13 (33.3%) | 42 (34.1%) | NS |
| Nausea | 7 (17.1%) | 8 (18.6%) | 0 (0%) | 15 (12.2%) | ∗∗ |
| Vomiting | 6 (14.6%) | 4 (9.3%) | 2 (5.1%) | 12 (9.8%) | NS |
| Flatulence | 4 (9.8%) | 4 (9.3%) | 0 (0%) | 8 (6.5%) | NS |
| Perianal discomfort/pain | 8 (19.5%) | 3 (7%) | 4 (10.3%) | 15 (12.2%) | NS |
| Sleep disturbance | 14 (34.1%) | 16 (37.2%) | 16 (37.2%) | 7 (17.9%) | NS |
| Dizziness | 7 (17.1%) | 3 (7.0%) | 1 (2.6%) | 11 (8.9%) | NS |
| Apathy | 9 (22.2%) | 5 (11.6%) | 2 (5.1%) | 16 (13.0%) | ∗∗∗ |
| Others | 2 (4.9%) | 2 (4.7%) | 2 (5.1%) | 6 (4.9%) | NS |
NS = statistically nonsignificant; ∗PEG-bisacodyl vs. PEG-ELS: p = 0.4, PEG-bisacodyl vs. NaPico+MgCit: p = 0.2, and PEG-ELS vs. NaPico+MgCit: p = 0.03; ∗∗PEG-bisacodyl vs. PEG-ELS: p = 0.9, PEG-bisacodyl vs. NaPico+MgCit: p = 0.06, and PEG-ELS vs. NaPico+MgCit: p = 0.04; ∗∗∗PEG-bisacodyl vs. PEG-ELS: p = 0.2, PEG-bisacodyl vs. NaPico+MgCit: p = 0.04, and PEG-ELS vs. NaPico+MgCit: p = 0.3.